You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Avelumab for treating metastatic Merkel cell carcinoma

  • Technology appraisal guidance
  • Reference number: TA517
  • Published:  11 April 2018
  • Last updated:  21 April 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final appraisal determination: 1
  3. Draft guidance: 1
  4. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 235 KB)

    Published:
    11 April 2018

Final appraisal determination: 1

  • Final appraisal determination: 1

  • Final appraisal determination document (PDF 430 KB)

    Published:
    01 March 2018
  • Committee papers (PDF 2.26 MB)

    Published:
    01 March 2018
  • Public committee slides (PDF 544 KB)

    Published:
    01 March 2018
  • Final appraisal determination document Managed Access Agreement (PDF 498 KB)

    Published:
    01 March 2018

Draft guidance: 1

  • Draft guidance: 1

  • Appraisal consultation document (PDF 420 KB)

    Published:
    27 November 2017
  • Public committee slides Clinical Presentation Slides (PDF 423 KB)

    Published:
    27 November 2017
  • Public committee slides Cost Presentation Slides (PDF 425 KB)

    Published:
    27 November 2017
  • Appraisal consultation document Equality Impact Assessment Form (PDF 220 KB)

    Published:
    27 November 2017
  • Committee papers (PDF 11.14 MB)

    Published:
    22 February 2018

Invitation to participate

  • Final scope (PDF 252 KB)

    Published:
    18 April 2017
  • Final matrix (PDF 262 KB)

    Published:
    18 April 2017
  • Final scope Comments table (PDF 308 KB)

    Published:
    18 April 2017
  • Equality impact assessment (Scoping) (PDF 174 KB)

    Published:
    25 April 2017
Back to top